IP Library Granted Patent US 11,116,792
Granted Patent B1
US 11,116,792 · App. 14/860,044 · Granted Sep 14, 2021

Cerium oxide nanoparticle formulation for use in skin radioprotection and associated methods

Inventors: Cheryl H. Baker (New Smyrna Beach, FL); D. Wayne Jenkins (Winter Park, FL); Sudipta Seal (Orlando, FL)
A61K33/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,116,792
App. No.
14/860,044
Granted
Sep 14, 2021
Kind
B1
Abstract

Cerium oxide nanoparticles have been found to enhance radiation-induced cancer cell death, while at the same time protecting normal tissue from radiation. The combination of cerium oxide nanoparticles with radiation has also been found to control and/or minimize the metastatic index. Cerium oxide nanoparticles have also been found to protect normal tissue subjected to irradiation from inflammation, and further to protect cells from reactive oxygen species. A cream comprising cerium oxide nanoparticles is formulated and used to protect skin against radiation-induced dermatitis.

Claims (18)

1. A method of treating or protecting skin or salivary gland tissue from ionizing radiation induced dermatitis or reduced salivary production in a human in need thereof comprising topically applying an effective dose of a cerium oxide nanoparticle cream composition to skin of the individual; wherein the cerium oxide nanoparticle cream composition comprises 12% w/v cerium oxide nanoparticles; and wherein the cerium oxide nanoparticle cream composition demonstrates little to no settling upon centrifugation for 15 minutes at 1380G.

2. The method of claim 1 , wherein the cerium oxide nanoparticles are non-agglomerated nanoparticles having a size in a range of 3 nm-5 nm.

3. The method of claim 1 , wherein the effective dose of cerium oxide nanoparticles comprises a dose in a range of 10 nM-200 μM.

4. The method of claim 1 , wherein the effective dose of cerium oxide nanoparticles comprises a dose of about 0.00001 mg/kg.

5. The method of claim 1 , wherein the effective dose of cerium oxide nanoparticles comprises a dose of about 0.01 mg/kg.

6. The method of claim 5 , wherein the microemulsion-derived cerium oxide nanoparticles have a size in a range of 3 nm-5 nm.

7. The method of claim 5 , wherein the effective dose of cerium oxide nanoparticles comprises a dose in a range of 10 nM-200 μM.

8. The method of claim 5 , wherein the effective dose of cerium oxide nanoparticles is administered before radiation exposure.

9. The method of claim 5 , wherein the effective dose of cerium oxide nanoparticles is administered during radiation exposure.

10. The method of claim 5 , wherein the effective dose of cerium oxide nanoparticles is administered after radiation exposure.

11. The method of claim 5 , wherein the effective dose of cerium oxide nanoparticles is administered bi-weekly for about 2 weeks prior to radiation exposure.

12. The method of claim 5 , wherein the effective dose of cerium oxide nanoparticles is administered bi-weekly for about 2 weeks during radiation exposure.

13. The method of claim 5 , wherein the effective dose of cerium oxide nanoparticles is administered bi-weekly for about 2 weeks after radiation exposure.

14. The method of claim 5 , wherein the cerium oxide nanoparticle cream composition further comprises 2% w/v of a sodium methacrylate acid-based surfactant.

15. The method of claim 5 , wherein the cerium oxide nanoparticle cream composition further comprises carbopol, polysorbate, coconut oil, aloe vera powder, shea butter cream, goat milk cream, triethanolamine, glycerin, cocoa butter, emulsifying wax, safflower oil, or combinations thereof.

16. The method of claim 8 , wherein the effective dose of cerium oxide nanoparticles is administered bi-weekly for about 2 weeks prior to radiation exposure.

17. The method of claim 9 , wherein the effective dose of cerium oxide nanoparticles is administered bi-weekly for about 2 weeks during radiation exposure.

18. The method of claim 10 , wherein the effective dose of cerium oxide nanoparticles is administered bi-weekly for about 2 weeks after radiation exposure.

Assignments (7)
CHANGE OF NAME Recorded Feb 2, 2022
From: BIOCURITY HOLDINGS, INC.
To: BIOCURITY PHARMACEUTICALS INC.
Reel/Frame 058946/0488 →
CHANGE OF NAME Recorded Dec 20, 2021
From: BIOCURITY, INC.
To: BIOCURITY PHARMACEUTICALS INC.
Reel/Frame 058549/0917 →
LICENSE Recorded Dec 3, 2021
From: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
To: BIOCURITY, INC.
Reel/Frame 058300/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: BAKER, CHERYL H.
To: BIOCURITY, INC.
Reel/Frame 058273/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: SEAL, SUDIPTA
To: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Reel/Frame 058274/0166 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: JENKINS, D. WAYNE
To: ORLANDO CANCER CENTER, INC.
Reel/Frame 058274/0049 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2021
From: ORLANDO CANCER CENTER, INC.
To: BIOCURITY, INC.
Reel/Frame 058274/0125 →
Continuity (3)
Continuation 14317895 · Jun 27, 2014
Continuation 13334911 · Dec 22, 2011
Provisional Application 61425904 · Dec 22, 2010